Applied DNA Sciences (APDN)
(Delayed Data from NSDQ)
$4.37 USD
-0.63 (-12.60%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $4.36 -0.01 (-0.23%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for Applied DNA Sciences Inc falls in the month of September.
All items in Millions except EPS data.
9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 | |
---|---|---|---|---|---|
Sales | 13 | 18 | 9 | 2 | 5 |
Cost Of Goods | 8 | 13 | 4 | 1 | 1 |
Gross Profit | 6 | 5 | 5 | 1 | 5 |
Selling & Adminstrative & Depr. & Amort Expenses | 16 | 19 | 18 | 14 | 14 |
Income After Depreciation & Amortization | -11 | -14 | -13 | -13 | -9 |
Non-Operating Income | 1 | 6 | -1 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -10 | -8 | -14 | -13 | -9 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -10 | -8 | -14 | -13 | -9 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -10 | -8 | -14 | -13 | -9 |
Depreciation Footnote | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -10 | -13 | -12 | -12 | -9 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -11 | -14 | -13 | -13 | -9 |
Earnings Per Share Data | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Average Shares | 13.08 | 8.97 | 6.92 | 3.92 | 0.92 |
Diluted EPS Before Non-Recurring Items | -0.76 | -1.18 | -1.82 | -3.32 | -10.46 |
Diluted Net EPS (GAAP) | -0.76 | -0.93 | -2.07 | -3.32 | -9.69 |
Fiscal Year end for Applied DNA Sciences Inc falls in the month of September.
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.89 | 0.78 | 2.92 | 4.41 |
Cost Of Goods | NA | 0.66 | 0.70 | 1.65 | 2.60 |
Gross Profit | NA | 0.23 | 0.08 | 1.27 | 1.81 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 4.02 | 4.25 | 4.13 | 4.51 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.79 | -4.17 | -2.86 | -2.70 |
Non-Operating Income | NA | 2.66 | 0.56 | -0.26 | 3.26 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -1.13 | -3.62 | -3.11 | 0.55 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | -0.03 | -0.03 | -0.01 | -0.04 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -1.13 | -3.62 | -3.11 | 0.55 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -1.11 | -3.59 | -3.10 | 0.59 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 13.67 | 13.57 | 12.91 | 12.91 |
Diluted EPS Before Non-Recurring Items | NA | -0.09 | -0.26 | -0.24 | -0.20 |
Diluted Net EPS (GAAP) | NA | -0.09 | -0.27 | -0.24 | 0.05 |